Analysts Are Building Momentum in These 3 Stocks

Analyst upgrades don’t always move stocks.

But when they start hitting in clusters, now we’re talking.

One upgrade can turn a few heads. A second starts to build conviction. And when multiple firms begin lifting ratings and price targets around the same stock in a tight window, sentiment can shift fast.

That’s why we track analyst momentum.

Not because it gives us the whole story. But because it can point us toward names where Wall Street’s tone is changing, the narrative is heating up, and a stock may be starting to wake up.

This week, only three stocks in our analyst screen picked up multiple upgrades over the past seven days.

And while all three are worth noting, that doesn’t mean all three are immediate buys.

At Trades of the Day, this is just one signal in the broader stack we use to separate a stock that’s merely interesting from one that deserves real capital.

The Stocks With Multiple Upgrades This Week

Looking at analyst activity over the last seven days, only three names in our screen received multiple upgrades:

If needed, swipe or scroll sideways to view the full table.

That’s a short list.

And that’s exactly why it matters.

Multiple upgrades in a short period are not normal. So when a stock shows up here, it usually means something in the story has changed — or that Wall Street believes something may be changing.

Whatever the reason, these are the names worth dragging out of the crowd and putting under the spotlight.

Why These 3 Names Made the Cut

All three stocks earned a place on the radar this week, but they got there in different ways.

1) STRO: The strongest same-day cluster

If you’re looking purely at analyst momentum, Sutro Biopharma (STRO) probably has the strongest signal of the group.

Why?

Because both upgrades hit on the same day.

• HC Wainwright upgraded the stock and lifted its target from $10 to $28
• Wells Fargo upgraded the stock and raised its target from $8 to $27

That kind of same-day double upgrade gets attention.

It suggests multiple firms are responding to the same evolving story at the same time — and when that happens, momentum can build quickly.

It also raises the obvious next research question: what changed enough to make both firms move on the same day?

Of course, STRO also looks like the highest-risk name on this list. It’s a small-cap biotech, its financials are still lumpy, and this is not the kind of stock conservative investors should chase casually. That doesn’t invalidate the analyst momentum. But it does mean the signal needs to be viewed through a much more speculative lens.

2) MLTX: Big targets, big volatility

MoonLake Immunotherapeutics (MLTX) also stands out.

Its two upgrades came a few days apart rather than on the same day:

• Rothschild & Co raised its target from $12 to $40
• Wolfe Research upgraded the stock to Outperform and raised its target from $12 to $24

That creates a target range of $24 to $40, with a midpoint around $32.

That’s a monster range.

And it tells you sentiment shifted in a big way.

It also tells you the next step is not to blindly chase the headline — it’s to dig into what made analysts so much more constructive in such a short period of time.

As always with biotech, the upside may look exciting on paper, but the volatility can be just as real.

3) Block: The quieter build

Then there’s Block (XYZ).

This one is less flashy than the biotech names, but still worth noting.

Both upgrades landed on March 18:

• Rothschild & Co upgraded the stock and moved its target from $45 to $55
• Truist Securities upgraded the stock and raised its target from $72 to $77

What stands out here is not the shock value of the targets.

It’s the fact that both firms moved on the same day, signaling that interest is building.

The wide target range also suggests there’s still some disagreement in how analysts are valuing the name.

That makes Block a little less dramatic than STRO or MLTX — but still worth flagging for deeper research.

Why This Signal Matters

This is exactly why we track analyst momentum as part of our trading strategy. When upgrades begin to cluster, they can act as a catalyst. They can draw fresh attention to a stock, reinforce a bullish narrative, and help move a name from “easy to ignore” to “suddenly in play.”

That doesn’t guarantee future gains, of course. Wall Street gets excited about plenty of things that go nowhere.

But this signal still matters because it tells us where sentiment is shifting.

The Takeaway

This week’s analyst screen gave us a short but useful list of stocks with multiple upgrades:

• STRO
• MLTX
• XYZ

Among them, STRO appears to have the strongest pure analyst-momentum signal thanks to its same-day double upgrade and tightly aligned targets.

MLTX may offer the biggest upside on paper, but it also comes with the kind of biotech volatility that can humble traders quickly.

And XYZ looks like a quieter name where analyst interest is beginning to build.

That makes all three worth watching.

Good trading,
Greg Patrick

P.S. Analyst momentum is one of the signals we watch closely because clusters of upgrades can help identify stocks that are starting to gain traction with Wall Street. But it’s only one piece of the puzzle. At Trades of the Day, we use analyst momentum as part of a broader Alpha Signal stack — because one bullish signal may be interesting, but multiple aligned signals — like insider buying, institutional accumulation and big option bets — are what really get our attention.